No Detail Found!

Comparative safety and efficacy of conventional interferon versus pegylated-interferon based therapy for HCV: A retrospective cohort study from Gujranwala, Pakistan

Author(s)
Usman Iftikhar Punjab University College of Pharmacy, University of the Punjab,Lahore,Pakistan
Mobasher Ahmed Punjab University College of Pharmacy, University of the Punjab,Lahore,Pakistan
Hamid Saeed Punjab University College of Pharmacy, University of the Punjab,Lahore,Pakistan
Nouman Saleem Punjab University College of Pharmacy, University of the Punjab,Lahore,Pakistan
Afzaal Bashir King Edward Medical University,Lahore,Pakistan
Muhammad Shahid Farooq King Edward Medical University,Lahore,Pakistan
Sairah Hafeez Kamran Faculty of Pharmaceutical & Allied Health Sciences, Lahore College for Women University,Lahore,Pakistan
Zikria Saleem Punjab University College of Pharmacy, University of the Punjab,Lahore,Pakistan; Faculty of Pharmacy, The University of Lahore, Pakistan
Abstract
Numerous studies on risk factors, clinical presentation and treatment of hepatitis C are known to the world. However, no data is available about the safety and efficacy of anti-hepatitis C therapy among the patients of Gujranwala, Pakistan. This retrospective study compared two dosage forms of interferon; conventional interferon (IR) and Pegylated interferon (PIR) in 370 Hepatitis C patients selected through non probability convenient sampling technique. Clinical data were collected related to therapy outcomes at the start of therapy, after each follow up and at the end of therapy. The study indicated that HCV 3 was the most prevalent genotype of hepatitis C. Main side effects associated with therapies were pain at injection site (PIR; 49%, IR; 48%), inflammation at injection site (PIR; 34%, IR; 48%), fever (PIR; 56.12%, IR; 61.5%), myalgia (PIR; 24.5%,IR; 22.99%), malaise (PIR; 7.14%, IR; 5.75%), anorexia (PIR; 46%, IR; 39%), vomiting (PIR; 43%, IR; 41%), irritability (PIR; 4%, IR; 11.5%) and impaired concentration (PIR; 13%, IR; 21). The sustained viral response rate was significantly better in PIR group as compared to IR group (PIR; 80.61%, IR; 66.67%). In conclusion Pegylated interferon based therapy showed better clinical response with less adverse events as compared to conventional interferon based therapy. However, there is dire need to shift from these intravenous dosage forms to relatively new oral dosage forms for the treatment of hepatitis C to further improve clinical outcome and minimize the risks of adverse events.
Publication Details
Page(s) 2037-2045
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: 5, Year: 2020

Request the full text from PASTIC

Keywords
Genotype, Polymerase chain reaction, Pegylated interferon, Sustained virological response, Conventional interferon
0

Citations

0

Downloads

195

Views